The CAIs were assessed for their ability to reduce the viability of the colon carcinoma HT-29 cell line, the breast cancer MDA-MB 231 cell line, and the ovarian cancer SKOV3 cell line, all expressing CA IX and CA XII isozymes [52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69]. This evidence concerns the gene CA9 and breast carcinoma.